| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
AtriCure (NASDAQ:ATRC) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
AtriCure beat estimated earnings by 8.7%, reporting an EPS of $-0.21 versus an estimate of $-0.23.
Revenue was up $18.52 million from the same period last year.
Last quarter the company beat on EPS by $0.11 which was followed by a 4.48% increase in the share price the next day.
Here's a look at AtriCure's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.31 | -0.29 | -0.34 | -0.18 |
| EPS Actual | -0.20 | -0.12 | -0.23 | -0.09 |
| Revenue Estimate | 96.73M | 97.49M | 87.53M | 87.66M |
| Revenue Actual | 98.29M | 100.92M | 93.49M | 88.03M |
To track all earnings releases for AtriCure visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ATRC
